Second medical use of a known compound is an important invention
to the pharmaceutical industry. However, due to the strict standard
of examination for pharmaceutical patents in China, a large number
of second medical use patent applications were rejected by the
CNIPA. Although a few second medical use applications survived from
the examination and were granted as patents in China, they were
frequently challenged and most of them were declared invalid in the
end. There were sayings by the pharmaceutical industry that Viagra
second medical use patent was probably the only one that survived
patent challenge in China.
Nevertheless, in the past two years, the CNIPA seemed to
gradually easing the examination standard for pharma patent
applications. In particular, the second medical use patent
owned by
the University of Bordeaux survived from a round of patent
challenge in 2020, and this decision was selected by the CNIPA as
one of TOP 10 exemplary Invalidation Cases for